Details of the Drug Combination
General Information of Drug Combination (ID: DCL3P1Y)
| Drug Combination Name |
Lithium Citrate Diethylcarbamazine
|
|||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indication |
|
|||||||||||||||||
| Component Drugs | Lithium Citrate | Diethylcarbamazine | ||||||||||||||||
| Small molecular drug | Small molecular drug | |||||||||||||||||
|
|
|||||||||||||||||
| 2D MOL | 2D MOL | |||||||||||||||||
| 3D MOL is unavailable | 3D MOL | |||||||||||||||||
| High-throughput Screening Result | Testing Cell Line: KBM-7 | |||||||||||||||||
| Zero Interaction Potency (ZIP) Score: 41.75 | ||||||||||||||||||
| Bliss Independence Score: 41.75 | ||||||||||||||||||
| Loewe Additivity Score: 52.06 | ||||||||||||||||||
| LHighest Single Agent (HSA) Score: 52.06 | ||||||||||||||||||
Molecular Interaction Atlas of This Drug Combination
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indication(s) of Lithium Citrate |
|
|||||||||||||||||||||||||||||||
| Indication(s) of Diethylcarbamazine |
|
|||||||||||||||||||||||||||||||
|
Diethylcarbamazine Interacts with 1 DTT Molecule(s)
|
||||||||||||||||||||||||||||||||
|
Diethylcarbamazine Interacts with 1 DOT Molecule(s)
|
||||||||||||||||||||||||||||||||
References
